CASI Pharmaceuticals (CASI) EBIAT (2022 - 2025)
Historic EBIAT for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$13.4 million.
- Pharmaceuticals' EBIAT fell 9203.16% to -$13.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$21.6 million, marking a year-over-year decrease of 14821.23%. This contributed to the annual value of -$39.3 million for FY2024, which is 24950.3% down from last year.
- Pharmaceuticals' EBIAT amounted to -$13.4 million in Q2 2025, which was down 9203.16% from -$10.8 million recorded in Q1 2025.
- In the past 5 years, Pharmaceuticals' EBIAT registered a high of $61.2 million during Q4 2022, and its lowest value of -$13.4 million during Q2 2025.
- In the last 4 years, Pharmaceuticals' EBIAT had a median value of -$6.4 million in 2023 and averaged $3.7 million.
- In the last 5 years, Pharmaceuticals' EBIAT surged by 26340.25% in 2024 and then crashed by 21282.54% in 2025.
- Pharmaceuticals' EBIAT (Quarter) stood at $61.2 million in 2022, then fell by 23.78% to $46.6 million in 2023, then tumbled by 114.94% to -$7.0 million in 2024, then plummeted by 92.03% to -$13.4 million in 2025.
- Its EBIAT was -$13.4 million in Q2 2025, compared to -$10.8 million in Q1 2025 and -$7.0 million in Q2 2024.